Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer

Journal of Clinical Pathology

Volumn 61, Issue 1, 2008, Pages 68-71

  Skaland, I ^a   Ovestad I ^a   Janssen, E A M ^a   Klos, J ^a   Kjellevold, K H ^a   Helliesen, T ^a   Baak, J P A ^a,b,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIGITAL IMAGING; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PATHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SCORING SYSTEM; BREAST TUMOR; EVALUATION; FEMALE; IMAGE PROCESSING; METABOLISM; METHODOLOGY; REPRODUCIBILITY;

BREAST NEOPLASMS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION, FLUORESCENCE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 38449103956     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2007.046763     Document Type: Article

References (11)

1. Perez EA. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer. Cancer Control 1999;6:233-40.
2. Gonzalez-Angulo AM, Hortobágyi GN, Esteva FJ. Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 2006;11:857-67.
3. Bloom K, Harrington D. Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol 2004;121:620-30.
4. Rhodes A, Borthwick D, Sykes R, et al. The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to tratuzumab. Am J Clin Pathol 2004;122:51-60.
5. Sidoni A, Ferri I, Cavaliere A, et al. Detection of HER-2/neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results. A further contribution to defining the role of fluorescent in situ hybridization. Anticancer Res 2006;26:2333-7.
6. Otsu N. A threshold method from gray-level histograms. Trans Syst Man Cybern 1979;9:62-6.
7. Sun XR, Wang J, Garner D, et al. Detection of cervical cancer and high grade neoplastic lesions by a combination of liquid-based sampling preparation and DNA measurements using automated image cytometry. Cell Oncol 2005;27:33-41.
8. Mattila R, Alanen K, Syrjanen S. DNA content as a prognostic marker of oral lichen planus with a risk of cancer development. Anal Quant Cytol Histol 2004;26:278-84.
9. Hanselaar AG, Bocking A, Gundlach H, et al. International Consensus Conference on the Fight Against Cervical Cancer, IAC Task Force 8 Summary, Chicago, Illinois, USA. Summary statement on quantitative cytochemistry (DNA and molecular biology): Task Force 8. Acta Cytol 2001;45:499-501.
10. Troxel ML, Bangs CD, Lawse HJ, et al. Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am J Clin Pathol 2006;126:709-16.
11. Hofmann MK, Gross C, Beyser K, et al. Predictive value of HercepTest IHC and Pathvysion FISH data: analysis from a trastuzumab phase II monotherapy study (abstract 740). Proc ASCO 2003;22:185.